Media headlines about Celsion (NASDAQ:CLSN) have trended positive this week, Accern Sentiment Analysis reports. The research firm scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Celsion earned a media sentiment score of 0.28 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 47.0792628645572 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Celsion (CLSN) remained flat at $$2.64 during trading hours on Friday. The company’s stock had a trading volume of 305,100 shares, compared to its average volume of 597,825. The stock has a market capitalization of $42.40, a PE ratio of -0.45 and a beta of 1.22. Celsion has a one year low of $1.24 and a one year high of $7.56.
Celsion (NASDAQ:CLSN) last issued its earnings results on Tuesday, November 14th. The biotechnology company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.17. Celsion had a negative net margin of 4,292.80% and a negative return on equity of 282.94%. analysts anticipate that Celsion will post -2.46 earnings per share for the current fiscal year.
Several equities research analysts have recently commented on CLSN shares. Maxim Group upgraded Celsion from a “hold” rating to a “buy” rating and set a $7.00 price objective for the company in a research note on Wednesday, October 4th. ValuEngine upgraded Celsion from a “strong sell” rating to a “sell” rating in a research note on Saturday, December 9th. Zacks Investment Research lowered Celsion from a “buy” rating to a “hold” rating in a research note on Thursday, January 11th. Finally, Oppenheimer started coverage on Celsion in a research note on Tuesday, November 21st. They issued an “outperform” rating and a $9.00 price objective for the company. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $11.90.
TRADEMARK VIOLATION WARNING: This story was first posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at https://www.thelincolnianonline.com/2018/01/19/celsion-clsn-receiving-favorable-press-coverage-study-finds.html.
Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).
Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.